
|Videos|December 9, 2021
Recent Data Surrounding the Appropriate Candidates for Long-Acting Cabotegravir for HIV Prevention
In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.
Advertisement
Pharmacy Times spoke with Dr. Elizabeth Sherman, PharmD, about her session at the ASHP Midyear 2021 conference, titled "Long Acting Antiretroviral Therapy for the Treatment and Prevention of HIV Infection”.
In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists as the Glue in Cardio-Kidney-Metabolic Care
2
Building a CDTM Program Means Starting Small
3
Extended-Interval Tarlatamab Dosing Offers Pharmacists More Flexible Administration Windows in SCLC
4
Pharmacists Weigh Health, Not Just Weight, in Obesity Care
5




































































































